Company news

MannKind Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

February 25, 2025

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

February 18, 2025

MannKind Expands Executive Leadership Team

January 5, 2025

MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

December 17, 2024

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

December 15, 2024

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

December 10, 2024

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

November 6, 2024

MannKind to Present at 2024 UBS Healthcare Conference

November 4, 2024

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

November 3, 2024

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

October 30, 2024

More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)

September 29, 2024

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

September 17, 2024

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

September 9, 2024

MannKind to Present at Upcoming Conferences

August 26, 2024

Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board

August 13, 2024

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

August 6, 2024

MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease

July 30, 2024

MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024

July 29, 2024

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions

June 21, 2024

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions

June 4, 2024

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

May 28, 2024

MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update

May 7, 2024

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

May 5, 2024

MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024

April 30, 2024

MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

April 29, 2024

MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease

April 28, 2024

MannKind Repays Certain Debt Obligations

April 2, 2024

MannKind Announces CFO Transition

March 25, 2024

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

March 10, 2024

MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8

March 4, 2024

MannKind Corporation Announces Participation at Upcoming Conferences

March 3, 2024

MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update

February 26, 2024

MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024

February 19, 2024

MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®

February 14, 2024

MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million

January 1, 2024

MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

December 27, 2023

MannKind Corporation Reports 2023 Third Quarter Financial Results

November 6, 2023

MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes

November 5, 2023

MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023

October 30, 2023

MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent

October 29, 2023

MannKind Corporation Reports 2023 Second Quarter Financial Results

August 6, 2023

MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference

July 31, 2023

MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023

July 30, 2023

MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)

June 21, 2023

Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone

June 10, 2023

Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer

May 23, 2023

MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

May 9, 2023

Mannkind Corporation Reports 2023 First Quarter Financial Results

May 8, 2023

MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023

May 1, 2023

Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer

March 26, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.